Ipamorelin is a synthetic growth-hormone secretagogue — a peptide that signals the pituitary to release more of its own growth hormone, without the cortisol, prolactin, or appetite spikes seen in older compounds. TelosRX reviews ipamorelin requests asynchronously, subject to medical approval by a licensed provider.
If you’ve read about growth hormone peptides, you’ve probably seen ipamorelin mentioned alongside CJC-1295, Sermorelin, or MK-677. They all aim at similar goals — improved body composition, recovery, sleep, and metabolic health — but the mechanisms and risk profiles differ significantly.
What follows is a clinical-team review of the questions we see most often about ipamorelin. The answers are sourced, evidence-graded, and honest about what we know versus what remains under-studied in humans.
What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide — five amino acids — classified as a growth hormone secretagogue receptor (GHSR) agonist. It was first described in preclinical research in the late 1990s as a selective, potent stimulator of growth hormone (GH) release from the pituitary gland. (Raun et al., 1999)
Unlike first-generation GH secretagogues, ipamorelin was designed to be selective. It stimulates GH release without the unwanted hormonal bystanders — specifically, it does not raise cortisol, aldosterone, or prolactin at therapeutic doses. This selectivity is considered its main clinical advantage over older compounds in the same class.
Ipamorelin is not FDA-approved for any human therapeutic use. It is available through licensed compounding pharmacies, subject to evaluation by a licensed provider.
How Does Ipamorelin Work?
Ipamorelin binds to growth hormone secretagogue receptors (GHSR-1a) on pituitary cells. This binding mimics the action of ghrelin — the hunger hormone that also drives pulsatile GH release — without triggering ghrelin’s appetite and cortisol effects to the same degree.
Two mechanisms work together when ipamorelin is administered:
- Direct GHSR activation: Ipamorelin binds GHSR-1a and stimulates GH secretion directly from somatotroph cells in the anterior pituitary.
- Somatostatin suppression: Ipamorelin reduces the inhibitory signal (somatostatin) that normally limits GH release, creating a permissive environment for a GH pulse.
The result is a GH pulse that occurs within 15–30 minutes of subcutaneous administration — mimicking the natural pulsatile pattern of GH release rather than producing a continuous elevated state. This pulsatile pattern is considered important for maintaining GH receptor sensitivity and avoiding tachyphylaxis (reduced response over time).
What Does the Research Show on Ipamorelin?
The most cited foundational study of ipamorelin (Raun et al., 1999) demonstrated significant longitudinal bone growth in rats at doses of 3–300 µg/kg — establishing its potency as a GH secretagogue and confirming dose-dependent GH and IGF-1 elevation. Human clinical trials are limited in number and sample size, which is a meaningful caveat that should accompany any claims about ipamorelin in people.
Available human data and clinical case series suggest ipamorelin at typical doses (100–300 µg administered subcutaneously) produces measurable GH pulses without meaningfully altering cortisol, prolactin, or thyroid-stimulating hormone. This hormonal selectivity is well-replicated across the available evidence base, even where the studies are small. (ClinicalTrials.gov: ipamorelin trials)
Preclinical research in animal models also shows effects on lean body mass, fat distribution, bone mineral density, and sleep architecture. Extrapolating these findings directly to humans requires caution — but they inform the clinical rationale for why ipamorelin is studied in contexts like body composition optimization, recovery support, and age-related GH decline.
What Are the Reported Benefits of Ipamorelin?
Based on the available evidence and clinical case patterns, reported benefits of ipamorelin include:
- Increased lean muscle mass: GH and IGF-1 promote protein synthesis and support muscle fiber development. Effects are gradual — changes in body composition typically take 8–16 weeks to become apparent.
- Reduced visceral fat: GH promotes lipolysis (fat breakdown) preferentially from visceral depots. Ipamorelin-driven GH pulses may support fat mobilization over time.
- Improved sleep quality: GH release is naturally concentrated during slow-wave sleep. Ipamorelin administration before bed aims to synchronize with this pattern and may improve sleep depth in some individuals.
- Faster tissue recovery: IGF-1 downstream from GH stimulates cellular repair pathways relevant to muscle, tendon, and connective tissue. For active individuals, this is often cited as a primary motivation for ipamorelin use.
- Skin and connective tissue changes: GH supports collagen synthesis. Some users report improvements in skin quality and joint comfort over extended protocols.
None of these benefits are guaranteed at the individual level. Ipamorelin is not FDA-approved for any of these indications, and the evidence supporting them ranges from preclinical animal data to limited human clinical series. Provider evaluation is essential before starting any protocol.
What Is the Standard Dosage of Ipamorelin?
| Parameter | Typical Range (from clinical literature and provider protocols) |
|---|---|
| Dose per injection | 100–300 µg subcutaneous |
| Frequency | 1–3 times daily (often once nightly before sleep) |
| Administration route | Subcutaneous injection (abdomen, thigh, or upper arm) |
| Onset of GH pulse | 15–30 minutes post-injection |
| Half-life of ipamorelin | Approximately 2 hours |
| Protocol length | 12–24 weeks (cycles vary by provider) |
| Timing consideration | Evening dosing supports natural nocturnal GH pulse |
These are reference ranges from published protocols and pharmacist review, not a personal prescription. Dosing must be individualized and is subject to provider approval. Do not self-prescribe or self-administer without clinical oversight.
What Side Effects Should I Know About?
Ipamorelin’s selectivity gives it a relatively favorable side-effect profile compared to older GH secretagogues. It does not significantly spike cortisol, prolactin, or appetite at therapeutic doses — the main mechanism-based risks of less selective compounds in this class.
Reported side effects across available data and clinical case series include:
- Injection site reactions: Mild redness, itching, swelling, or tenderness. Typically transient and manageable with proper injection technique.
- Headache: Reported in some users, particularly early in a protocol. Usually resolves within the first few weeks.
- Transient lightheadedness: Related to early GH pulses; generally resolves as the body adjusts.
- Mild nausea: Infrequent, usually limited to the first days of use.
- Water retention: GH-mediated fluid retention can occur, typically mild and dose-dependent.
Long-term safety data in humans is limited. The absence of reported serious adverse events in short-term studies is not the same as a confirmed long-term safety profile. Ongoing provider monitoring is appropriate for any extended peptide protocol.
How Does Ipamorelin Compare to Other GH-Stimulating Peptides?
Ipamorelin is often stacked with or compared to CJC-1295, Sermorelin, and MK-677. Each has a distinct mechanism and trade-off profile.
- CJC-1295: A GHRH (growth hormone-releasing hormone) analogue — stimulates GH through a different receptor than ipamorelin. Often used together with ipamorelin because the two mechanisms are synergistic: GHRH primes the pituitary and ipamorelin triggers the pulse. See our CJC-1295 and Ipamorelin stack research guide for more detail.
- Sermorelin: A GHRH analogue with a shorter half-life than CJC-1295. Less expensive, but requires more frequent dosing. Evidence in humans is more extensive than for ipamorelin.
- MK-677 (Ibutamoren): An oral GH secretagogue that activates the same GHSR receptor as ipamorelin. Convenience of oral dosing, but notable appetite stimulation and potential insulin-resistance signals at higher doses. See our MK-677 overview for the evidence breakdown.
Can Ipamorelin Be Stacked With CJC-1295?
Yes — this is one of the most commonly used combination protocols in the GH-support space, and the rationale is straightforward. CJC-1295 acts on GHRH receptors; ipamorelin acts on GHSR. Together they work through two different pathways to amplify GH release more effectively than either does alone.
Common stacking protocols use ipamorelin (100–200 µg) alongside CJC-1295 (100 µg) administered together subcutaneously, typically before sleep. The combined GH response is meaningfully larger than with either peptide individually. Both remain not FDA-approved and require compounding and provider-issued prescription.
Who Is a Candidate for Ipamorelin Therapy?
Ipamorelin is studied in contexts including age-related GH decline, body composition optimization (particularly lean mass and fat ratio), recovery support for active individuals, and sleep quality concerns linked to GH deficiency patterns.
It is not appropriate for individuals with active malignancy (GH stimulation is theoretically contraindicated), active pituitary pathology, or pregnancy. It should be used with caution in those with diabetes or insulin resistance, where GH’s counter-regulatory effects on insulin sensitivity warrant monitoring.
Whether ipamorelin is appropriate for your specific situation requires evaluation by a licensed provider — one who can review your labs, health history, and goals asynchronously through the TelosRX platform.
How Is Ipamorelin Administered at TelosRX?
TelosRX operates as an asynchronous telehealth platform — no real-time appointment is required. You complete a health intake, a licensed provider reviews your case on their schedule, and if approved, a compounded ipamorelin protocol is issued with full instructions.
Administration is subcutaneous injection. Reconstitution instructions (most compounded peptides come as lyophilized powder requiring bacteriostatic water) are included with the dispensed medication. Injection technique is documented in your provider-issued materials.
Access to ipamorelin at TelosRX is subject to medical approval by a licensed provider. Approval is not guaranteed. Compounded ipamorelin is not FDA-approved.
When Should I Expect to See Results?
GH-axis changes are not rapid. Most people who respond to ipamorelin notice subtle shifts — improved sleep quality, faster recovery from exercise, slight changes in energy — within 4–8 weeks. Body composition changes (visible lean mass gain or fat reduction) typically require 12–20 weeks of consistent protocol adherence.
Individual variability is significant. Age, baseline GH status, diet, training, and protocol adherence all influence outcomes. Realistic expectations are an important part of any provider conversation before starting.
Frequently Asked Questions
Can you take ipamorelin every day?
Yes — daily administration is part of most clinical protocols, typically once or twice daily. The peptide’s short half-life (~2 hours) means multiple doses per day are sometimes used to maintain cumulative GH pulse frequency. Exact frequency is set by the prescribing provider based on your individual goals and baseline. All use is subject to provider-issued prescription.
Does ipamorelin increase appetite?
Unlike ghrelin (the hunger hormone it partially mimics) and MK-677 (which drives significant appetite stimulation), ipamorelin does not significantly increase appetite at standard doses. This selectivity is one of the reasons it’s favored over GHSR agonists with stronger ghrelin-like effects. Some users report mild hunger changes early in a protocol, but appetite stimulation is not a primary characteristic of ipamorelin at therapeutic doses.
Is ipamorelin safe to use with testosterone replacement therapy?
Many provider protocols include ipamorelin alongside TRT (testosterone replacement therapy), as the two work through different axes and may have complementary effects on body composition and recovery. However, combining hormonal therapies always requires individual clinical assessment. No protocol should be started without provider review of your full medication list, labs, and health history. Both remain subject to medical approval by a licensed provider.
What happens when you stop ipamorelin?
Stopping ipamorelin does not suppress endogenous GH production the way exogenous growth hormone does — ipamorelin stimulates the pituitary to release its own GH rather than replacing it. When you discontinue, your pituitary resumes its baseline GH secretion pattern. Any body composition or performance changes accumulated during the protocol are not permanent without maintenance of diet and training, but the pituitary axis is not expected to be suppressed by ipamorelin discontinuation.
Does ipamorelin raise cortisol or prolactin?
No meaningful cortisol, aldosterone, or prolactin elevation has been demonstrated at therapeutic ipamorelin doses in available studies. This hormonal selectivity is the defining clinical advantage of ipamorelin over older GH secretagogues. It was specifically engineered to activate GHSR without triggering the cortisol/prolactin spikes seen in earlier compounds like GHRP-6 and GHRP-2, though monitoring is still appropriate during any protocol.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.